e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.
You may also be interested in...
Rhenovia Aims To Boost Biosimulation Use In CNS R&D
France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.
Rhenovia To Boost Biosimulation Use In CNS R&D
France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.
Clinigen Raises $80 Mil. In Rare U.K. Flotation While Europe's Wellington Partners Raises $91 Mil. For New Life Sciences Fund
Hopes in Europe’s cash-strapped biotech sector were rekindled when specialty drug and contract services company Clinigen said it will be Britain’s first public pharma listing in five years and by investors from Europe, the U.S. and the Middle East piling into a new life sciences investment fund set up by pan-European VC firm Wellington Partners.